Literature DB >> 29160730

Reply to Muraca et al.: Exosome Treatment of Bronchopulmonary Dysplasia: How Pure Should Your Exosome Preparation Be?

S Alex Mitsialis1,2, Gareth R Willis1,2, Angeles Fernandez-Gonzalez1,2, Stella Kourembanas1,2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29160730      PMCID： PMC6020415          DOI： 10.1164/rccm.201710-2066LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  3 in total

Review 1.  Therapeutic Applications of Extracellular Vesicles: Perspectives from Newborn Medicine.

Authors:  Gareth R Willis; Stella Kourembanas; S Alex Mitsialis
Journal:  Methods Mol Biol       Date:  2017

2.  Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation.

Authors:  Gareth R Willis; Angeles Fernandez-Gonzalez; Jamie Anastas; Sally H Vitali; Xianlan Liu; Maria Ericsson; April Kwong; S Alex Mitsialis; Stella Kourembanas
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

3.  Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency.

Authors:  Gareth R Willis; Stella Kourembanas; S Alex Mitsialis
Journal:  Front Cardiovasc Med       Date:  2017-10-09
  3 in total
  2 in total

1.  Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6.

Authors:  Sushma Chaubey; Sam Thueson; Devasena Ponnalagu; Mohammad Afaque Alam; Ciprian P Gheorghe; Zubair Aghai; Harpreet Singh; Vineet Bhandari
Journal:  Stem Cell Res Ther       Date:  2018-06-26       Impact factor: 6.832

Review 2.  Mesenchymal Stem Cell-Derived Extracellular Vesicles for the Treatment of Bronchopulmonary Dysplasia.

Authors:  Yufeng Xi; Rong Ju; Yujia Wang
Journal:  Front Pediatr       Date:  2022-04-04       Impact factor: 3.569
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.